

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Alan Daniel Brown, et al :

APPLICATION NO.: To Be Assigned : Examiner: To Be Assigned

FILING DATE: Herewith : Group Art Unit: To Be Assigned

TITLE: Indole Derivatives Useful For The Treatment of :
Diseases

Mail Stop Patent Applications
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: March 12, 2004

Robert T. Ronau
Robert T. Ronau
Attorney for Applicant(s)
Reg. No. 36,257

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-5910

EXPRESS MAIL NO. EV271824995US

INFORMATION DISCLOSURE CITATION <small>Page 1 of 3</small> (Use several sheets if necessary)				ATTY. DOCKET NO. PC25600A				SERIAL NO. To Be Assigned			
				APPLICANT Alan Daniel Brown, et al.							
				FILING DATE Herewith				GROUP To Be Assigned			

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO	
	EP	0	8	0	1	0	6	0	15 Oct 97	EPO	C07D	209/42			
	EP	0	8	2	2	1	8	5	4 Feb 98	EPO	C07D	209/42			
	WO	9	1	1	1	1	7	2	8 Aug 91	International	A61K	9/00			
	WO	9	4	0	2	5	1	8	3 Feb 94	International	C08B	37/16			
	WO	9	8	5	5	1	4	8	10 Dec 98	International	A61K	47/48			

ARTICLES			
			Berge et al., J. Pharm, Sci., 1977, 66, pg 1-19
			Kobilka et al., PNAS 84, 1987, pgs 46-50
			Bouvier et al., Mol. Pharmacol, 33, 1988, pgs 133-139
			Barnes, P. J. Chest, 1997, 111:2, pp 17S-26S
			Bryan, S.A. et al., Expert Opinion on Investigational Drugs, 2000, 9:1, pp 25-42
			Tetrahedron Letters, 1994, 35(50), 9375

EXAMINER	DATE CONSIDERED
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

EXPRESS MAIL NO. EV27182499SUS